These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for advanced hepatocellular carcinoma, where are we? Zhang L; Ding J; Li HY; Wang ZH; Wu J Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188441. PubMed ID: 33007432 [TBL] [Abstract][Full Text] [Related]
5. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
6. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Wang L; Wang FS Hepatol Int; 2019 Sep; 13(5):521-533. PubMed ID: 31352593 [TBL] [Abstract][Full Text] [Related]
7. Advances in novel systemic therapies for advanced hepatocellular carcinoma. Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677 [TBL] [Abstract][Full Text] [Related]
8. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis. Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410 [TBL] [Abstract][Full Text] [Related]
9. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985 [TBL] [Abstract][Full Text] [Related]
10. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
11. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Feng MY; Chan LL; Chan SL Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172 [TBL] [Abstract][Full Text] [Related]
12. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389 [TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Li Q; Han J; Yang Y; Chen Y Front Immunol; 2022; 13():1070961. PubMed ID: 36601120 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapies for hepatocellular carcinoma. Liu JKH; Irvine AF; Jones RL; Samson A Cancer Med; 2022 Feb; 11(3):571-591. PubMed ID: 34953051 [TBL] [Abstract][Full Text] [Related]
16. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151 [TBL] [Abstract][Full Text] [Related]
17. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. Li SQ; Yang Y; Ye LS World J Gastroenterol; 2022 Nov; 28(42):6034-6044. PubMed ID: 36405383 [TBL] [Abstract][Full Text] [Related]
18. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177 [TBL] [Abstract][Full Text] [Related]
19. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917 [TBL] [Abstract][Full Text] [Related]
20. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Perera S; Kelly D; O'Kane GM Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]